Trial Profile
A randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Pharmacogenomic; Therapeutic Use
- 15 Dec 2009 Results have been published in the journal Clinical Cancer Research.
- 15 Dec 2009 Status changed from active, no longer recruiting to completed. According to results published in the journal Clinical Cancer Research.
- 14 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.